- Home
- LXRX vs CTNM Comparison
LXRX vs CTNM Comparison
Compare LXRX & CTNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LXRX | CTNM |
|---|---|---|
| Founded | 1995 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 547.4M | 507.0M |
| IPO Year | 2000 | 2024 |
Fundamental Metrics
Financial Performance| Metric | LXRX | CTNM |
|---|---|---|
| Price | $1.68 | $13.01 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 5 |
| Target Price | $4.15 | ★ $19.80 |
| AVG Volume (30 Days) | ★ 2.3M | 180.4K |
| Earning Date | 06-08-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.78 | 0.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $49,803,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $22.16 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 60.24 | N/A |
| 52 Week Low | $0.32 | $3.35 |
| 52 Week High | $1.83 | $16.33 |
Technical Indicators
Market Signals| Indicator | LXRX | CTNM |
|---|---|---|
| Relative Strength Index (RSI) | 62.33 | 41.59 |
| Support Level | $1.08 | $10.39 |
| Resistance Level | $1.83 | $13.18 |
| Average True Range (ATR) | 0.13 | 1.12 |
| MACD | 0.01 | -0.28 |
| Stochastic Oscillator | 71.62 | 1.78 |
Price Performance
Historical ComparisonAbout LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, also developing LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.
About CTNM Contineum Therapeutics Inc.
Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.